How to Choose a Compounding Pharmacy for Semaglutide in 2026: The Seven Criteria That Actually Matter

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 9 sources cited

Key Takeaways

• The FDA removed semaglutide from its drug shortage list in February 2025, which materially changed the legal status of compounded semaglutide. Many pharmacies that compounded during the shortage are no longer permitted to compound the standard formulation under section 503A.
• Legitimate compounding for semaglutide in 2026 is narrower than during the shortage. Most permissible compounding now involves clinical justification (allergy to an excipient, dose not commercially available, individual prescription not equivalent to a copy of an FDA-approved product).
• The seven criteria that matter when choosing a compounding pharmacy: regulatory designation (503A versus 503B), state board status, USP <797> compliance, third-party sterility and potency testing, supply-chain transparency on API source, beyond-use dating practices, and a verifiable physical address.
• Patients should not assume a website that lists "compounded semaglutide" represents a legitimate, properly-licensed operation. The post-shortage landscape includes legitimate clinical compounders, gray-market operations, and outright counterfeit suppliers.
• A specific, falsifiable prediction: by Q4 2026, the share of U.S. compounded semaglutide volume falling under proper clinical justification will be under 30% of pre-shortage compounding volume. The rest will have transitioned to FDA-approved branded supply, exited the market, or moved underground.

Direct answer (40-60 words)

The best compounding pharmacy for semaglutide in 2026 is one that is properly licensed (503A or registered 503B), USP <797> compliant, posts third-party sterility and potency testing, sources active ingredient through a verifiable supply chain, and operates within current FDA and state board boundaries. The post-shortage regulatory landscape has narrowed legitimate compounding significantly.

Table of contents

1. The 30-second answer
2. What changed in 2025: the shortage list removal
3. 503A versus 503B: why the distinction matters
4. The seven criteria for evaluating a compounding pharmacy
5. The questions to ask before any first fill
6. Red flags that signal a pharmacy to avoid
7. The Three Failure Modes of Post-Shortage Compounding framework
8. What most articles get wrong about "best compounding pharmacy" lists
9. Decision tree: should you use compounded semaglutide at all
10. Steelman the contrary view: why legitimate compounding still has a role
11. FormBlends clinical perspective on supply-chain quality
12. FAQ
13. Sources
14. Footer disclaimers

What changed in 2025: the shortage list removal

The legal status of compounded semaglutide changed materially in early 2025. Here is the timeline:

• 2022 to 2024: Semaglutide was on the FDA drug shortage list. Section 503A and 503B compounding pharmacies were permitted to compound semaglutide as a non-FDA-approved alternative under shortage provisions.
• February 21, 2025: The FDA announced it had resolved the semaglutide shortage. With shortage status removed, the legal pathway for routine compounding of semaglutide narrowed substantially.
• April 22, 2025 (503A) and May 22, 2025 (503B): The FDA's enforcement discretion windows for compounded semaglutide expired. After these dates, compounding semaglutide as an "essentially a copy" of the commercially available product is generally not permitted under 503A or 503B unless specific clinical justification exists.

What this means in 2026: a compounding pharmacy that produces semaglutide outside of specific clinical exceptions (allergy to an excipient in the FDA-approved product, a dose not commercially available, a true individualized clinical need documented in the prescription) is operating outside the FDA's permitted scope.

The pharmacies that remain in legitimate semaglutide compounding in 2026 are narrower in scope and almost always limit production to specific clinical scenarios rather than offering a generic compounded product to anyone with a prescription.

503A versus 503B: why the distinction matters

U.S. compounding pharmacies fall into two regulatory categories under the Drug Quality and Security Act of 2013.

Section 503A pharmacies are traditional compounding pharmacies regulated primarily by state boards of pharmacy, with FDA oversight on specific compliance questions. They can compound a drug for an individual patient under a specific prescription. They cannot mass-produce.

Section 503B outsourcing facilities are FDA-registered, FDA-inspected facilities that can compound in larger batches without patient-specific prescriptions, but only from a published list of bulk drug substances and only under stricter quality controls (USP <797>, USP <800>, current Good Manufacturing Practice, third-party testing).

The distinction matters because:

• 503B facilities are subject to FDA inspection and publish FDA Form 483 inspection results. You can look them up.
• 503A pharmacies are inspected by state boards, not FDA, and inspection records may be less accessible.
• 503B compounded products require third-party sterility, potency, and endotoxin testing per batch.
• 503A products may or may not have third-party testing depending on the pharmacy's voluntary practice.

For a patient evaluating a compounding pharmacy, knowing which designation it operates under is the first question.

The seven criteria for evaluating a compounding pharmacy

The seven criteria below are not based on a public ranking. They are based on the same questions a state board of pharmacy or FDA inspector would ask.

A pharmacy that scores well on all seven is the candidate to consider. A pharmacy that fails on any one of these criteria is a pharmacy to avoid, even if it offers a lower price.

The single most informative question is the third-party testing question. A legitimate compounder posting Certificate of Analysis (CoA) results from an independent ISO-accredited lab for sterility and potency on each batch is signaling that they want to be checked. A pharmacy that does not post CoAs, or that posts only "internal testing" results, is not signaling that confidence.

The questions to ask before any first fill

Before sending your prescription to any compounding pharmacy, ask the pharmacist directly:

1. Is your pharmacy licensed as 503A or 503B? Can you provide your state board license number and FDA registration number if applicable?
2. When was your most recent state board inspection? Were there findings? Are they resolved?
3. Do you publish Certificates of Analysis from a third-party ISO-accredited lab for sterility, potency, and endotoxin testing? Can I see one for the lot I will receive?
4. Where is your active pharmaceutical ingredient (API) sourced? Is the supplier FDA-registered?
5. What is the beyond-use date you assign to the compounded product? What is the basis for that BUD?
6. What is the clinical justification for compounding semaglutide rather than dispensing the FDA-approved product? Is the prescription documented as "essentially a copy" or as an individualized clinical need?
7. What is your physical address? Are you the dispensing facility, or are you shipping from elsewhere?

A pharmacy that answers these questions clearly and provides documentation is a pharmacy worth considering. A pharmacy that deflects, delays, or refuses to answer is one to avoid.

Red flags that signal a pharmacy to avoid

Specific signals that should disqualify a pharmacy from consideration:

• No state board license number on the website or order page. Legitimate pharmacies list their license. This is required in many states.
• Active ingredient sourced from non-FDA-registered API suppliers. Some compounders source semaglutide API from Chinese or Indian suppliers that are not FDA-registered. The API may or may not be the same molecule. Quality is not guaranteed.
• No third-party CoA available. A pharmacy that says "we test internally" but cannot provide independent lab results is not meeting the bar.
• Aggressive beyond-use dating. A 60-day to 90-day BUD on a multi-dose vial of compounded peptide is on the edge of standards. Some pharmacies post 180-day BUDs that exceed reasonable USP <797> guidance.
• Direct-to-consumer sales without prescription verification. Compounded medications require an individual prescription from a licensed prescriber. Any operation that sells "compounded semaglutide" without a real prescription verification step is operating outside the law.
• Shell-company structure or PO Box address. Legitimate pharmacies have inspectable physical facilities. PO Box addresses or international shipping origins are red flags.
• Marketing claims of equivalence to brand-name products. Compounded semaglutide is not equivalent to FDA-approved semaglutide. Pharmacies that claim equivalence are misleading patients.
• Unusually low prices that undercut peers materially. Quality testing and sourcing have real costs. A pharmacy charging far below market rate is cutting corners somewhere.

The Three Failure Modes of Post-Shortage Compounding framework

[Diagram suggestion: a 3-column visual labeled Past, Present, Future, showing the 2022-2024 shortage period with broad legitimate compounding, the 2025 enforcement window with narrowing scope, and the 2026+ post-shortage state with legitimate compounding limited to clinical exceptions versus gray-market operations versus outright counterfeit, separated by quality-assurance bar height.]

We see three distinct failure patterns in patients who seek compounded semaglutide in the post-shortage era. We call these the Three Failure Modes of Post-Shortage Compounding.

Failure Mode 1: Legacy-Pharmacy Inertia. A pharmacy that compounded legitimately during the shortage continues compounding in 2026 without updating its operational scope, hoping enforcement does not arrive. Patients filling at this pharmacy are receiving product compounded under questionable current legal status. The pharmacy may be inspected and shut down; the patient's supply chain ends without warning.

Failure Mode 2: Gray-Market Migration. During the shortage, some operations were structured as compounding pharmacies in name only, with limited cleanroom infrastructure, no CoA testing, and aggressive marketing. Post-shortage, these operations have moved further offshore or behind shell companies. The product purity, potency, and sterility are unverifiable. Adverse events documented in FAERS during 2024 to 2025 included contaminated product from these operations.

Failure Mode 3: Counterfeit Substitution. The most dangerous mode: a website that markets "compounded semaglutide" but ships product manufactured outside any pharmacy regulatory framework, sometimes containing adulterated or substituted active ingredients (different peptides, wrong concentration, contamination). The FDA has issued warnings about counterfeit semaglutide products marketed online. Patients have no way to identify counterfeit before injection.

The seven evaluation criteria above are designed specifically to filter out modes 2 and 3, and to identify whether a pharmacy in mode 1 has updated its practice. A pharmacy that scores well on all seven criteria is unlikely to be operating in any of the three failure modes.

What most articles get wrong about "best compounding pharmacy" lists

The most common error in published "best compounding pharmacy" content is presenting a numbered list of specific pharmacy names as if they had been independently evaluated.

In practice, almost every "top 10 compounding pharmacy" article online is either:

• An advertorial (the pharmacies on the list paid for placement, directly or through affiliate referral fees);
• A list compiled from public marketing pages without any actual due diligence;
• An outdated 2023 or 2024 list that was written during the shortage and has not been updated to reflect post-February 2025 regulatory changes.

A patient making a decision based on these lists is not actually getting independent evaluation. They are getting a marketing surface.

The second common error is treating the regulatory question as binary (legal versus illegal) when the actual landscape is graduated. A pharmacy may be legitimately licensed and in good standing while still operating outside post-shortage permitted scope. A pharmacy may have a state board license while having a track record of inspection findings that should concern a buyer. The right framing is criteria-based evaluation, not a yes-or-no answer.

The third common error is omitting the clinical-justification question. Compounding for an individual patient under a specific clinical need is permitted. Compounding for marketing reasons (offering a generic compounded product to anyone with a prescription, regardless of clinical justification) is not. Articles that conflate the two mislead patients about what they are buying.

The fourth common error is presenting compounded semaglutide as equivalent to FDA-approved semaglutide. The FDA prescribing information is for the brand-name product. Compounded products have not undergone the same review, and individual product quality varies by pharmacy. Equivalency claims are inappropriate.

Decision tree: should you use compounded semaglutide at all

[Diagram suggestion: a top-down branching flowchart starting at "Why are you considering compounded semaglutide?" with branches for (cost, allergy/excipient, dose unavailable, supply concern), each running through a clinical-justification check and a regulatory-status check, ending at branch outcomes (proceed with vetted compounder, switch to brand, switch to alternative agent).]

If you are considering compounded semaglutide in 2026, follow this branching logic.

Step 1: Why are you considering compounded?

• Cost only: Brand-name semaglutide remains expensive. But generic-pricing dynamics are changing in adjacent products (generic liraglutide arrived in late 2024). The right question is not "is compounded cheaper than brand" but "what is the total annual cost path on each option, including risk of disrupted supply if compounding is enforced against."
• Allergy or excipient issue: This is one of the few clinical justifications that supports legitimate compounding. The prescription should document the specific excipient and the medical reason for avoidance. Discuss with your prescriber whether a compounded alternative is warranted.
• Dose not commercially available: A patient prescribed an unusual dose not made by the manufacturer can have it compounded. This is permitted clinical justification.
• Supply concern: Branded semaglutide is no longer on the FDA shortage list as of February 2025. Supply concern as a justification has weakened materially.

Step 2: Is the clinical justification documented?

If your prescription is documented as "essentially a copy" of the commercially available product without specific clinical justification, the compounding is on weak regulatory ground. Discuss with your prescriber whether to update the prescription with documented clinical rationale or switch to the FDA-approved product.

Step 3: Apply the seven criteria.

For any pharmacy you are considering, run through the seven evaluation criteria. Do not proceed with a pharmacy that fails on regulatory designation, third-party testing, or physical-address verifiability.

Step 4: Confirm the supply chain.

Ask the pharmacy for the API source and the lot CoA. A pharmacy that cannot or will not provide these is not a pharmacy to use.

Step 5: Plan the contingency.

Even with a vetted compounder, regulatory enforcement of the post-shortage compounding rules is dynamic. Have a contingency plan: an FDA-approved alternative your insurance covers, a prescriber willing to switch you on short notice, and a 60-day buffer of supply where reasonable.

Steelman the contrary view: why legitimate compounding still has a role

A thoughtful clinical pharmacist might argue that the post-shortage tightening goes too far, and that legitimate compounding still has a meaningful patient role in 2026.

The strongest case: individualized medicine has always required some compounding. Patients with rare allergies to excipients, patients needing non-standard doses, patients in pediatric or geriatric populations where adjusted formulations are necessary, all have benefited from compounding for decades. Section 503A exists for good reasons, and narrowing it too aggressively reduces patient access without proportional safety gain.

For semaglutide specifically, the case for legitimate compounding includes patients who developed injection-site reactions to a polysorbate or phenol component of the FDA-approved formulation, patients prescribed off-label doses (such as a 0.125 mg starter dose for extreme sensitivity that is not commercially available), and patients in research-clinical contexts. These uses are not gray-market. They are genuine clinical compounding.

The case against expansive interpretation: the volume of compounded semaglutide produced during 2022 to 2024 was many orders of magnitude larger than the population with documented clinical justification. Most of that volume was driven by cost arbitrage, not clinical need. The post-February 2025 enforcement is correcting that arbitrage, not eliminating clinical compounding.

The middle ground: post-shortage, legitimate clinical compounding for documented individual needs continues to be appropriate. Compounded semaglutide as a generic cost-saving alternative for any patient with a prescription is not. A patient with a documented clinical need can confidently work with a properly-vetted compounding pharmacy. A patient with no clinical need beyond cost is on weaker ground.

FormBlends clinical perspective on supply-chain quality

> > The pattern we watch for in patient outcomes: pharmacies that publish CoAs, that are willing to walk a patient through their inspection record, and that have transparent API sourcing produce noticeably fewer adverse-event reports per patient than pharmacies that obscure these details. We see this consistently. The right question for a patient is not "is this pharmacy famous" or "does this pharmacy have a slick website." The right question is "would this pharmacy welcome a state board inspection tomorrow."

FAQ

Is compounded semaglutide still legal in 2026? It is legal under specific clinical justifications (excipient allergy, non-commercial dose, individualized medical need). It is generally not legal as an "essentially a copy" of the FDA-approved product without clinical justification, since the shortage was resolved in February 2025 and the FDA's enforcement discretion windows expired in spring 2025.

What is the difference between 503A and 503B compounding pharmacies? 503A pharmacies compound for individual patients under specific prescriptions and are regulated primarily by state boards. 503B facilities are FDA-registered outsourcing facilities that can compound in batches under stricter quality controls and FDA inspection. 503B is generally a higher-quality regulatory tier.

Should I trust a compounding pharmacy that does not post Certificates of Analysis? No. Independent third-party testing for sterility, potency, and endotoxin is the most reliable signal of quality. A pharmacy that cannot or will not provide CoAs is signaling a quality posture that does not match the product they are dispensing.

Where does compounded semaglutide active ingredient come from? Active pharmaceutical ingredients (APIs) are sourced from various global suppliers. Legitimate compounders source from FDA-registered API suppliers and require Certificates of Analysis from the supplier on each lot. Pharmacies that source from non-registered suppliers are not meeting the standard.

How can I verify a compounding pharmacy's license? State board of pharmacy websites publish licensee directories. Search for the pharmacy's name and address; the state board listing will show license status, expiration, and any disciplinary history. For 503B facilities, the FDA publishes a registered outsourcing facility list with inspection records.

What is USP <797>? USP <797> is the U.S. Pharmacopeia chapter that sets standards for sterile compounding, including environmental controls, beyond-use dating, personnel training, and quality assurance. Compliance is required for sterile compounding (which includes all injectable medications). State boards inspect for USP <797> compliance during routine inspections.

Are all compounded semaglutide products the same? No. Concentration, excipients, beyond-use dating, and quality controls vary by pharmacy. Two patients with prescriptions filled at different compounders can receive products with different shelf lives, different injection volumes per dose, and different impurity profiles.

What should I do if I have been using compounded semaglutide and the pharmacy stops compounding? Talk to your prescriber about transitioning to FDA-approved semaglutide. The transition typically involves matching the dose-equivalent of the FDA-approved product (since compounded doses sometimes do not align with the brand's titration steps) and may require prior authorization through your insurance.

Is compounded semaglutide covered by insurance? Almost never. Compounded semaglutide is not FDA-approved, and insurance plans rarely cover non-FDA-approved drugs. Patients pay cash, often through the compounding pharmacy directly or through a telehealth platform that bundles the medication into a subscription cost.

Is the dose schedule the same for compounded and brand-name semaglutide? The active molecule is semaglutide in both cases, so the pharmacology is similar. But compounded products are dispensed in vials with U-100 insulin syringe administration, requiring the patient to draw the right unit volume. Brand-name semaglutide is dispensed in pre-filled pens with dose-dialing. Errors are more common with vial-and-syringe administration.

What are the documented risks of compounded semaglutide? Risks include sterility failures (contamination producing injection-site infection or systemic infection), potency variation (patients receiving more or less drug than expected), wrong-molecule substitution (counterfeit products containing different peptides), and unregulated excipient mixtures. The FDA has issued warnings about adverse events linked to compounded semaglutide products from various sources.

How do I find out if my compounding pharmacy has had inspection findings? For 503B facilities, FDA Form 483 inspection observations are published on the FDA website. For 503A pharmacies, request inspection records from your state board of pharmacy. The pharmacy itself should be willing to discuss recent inspections; refusal is a red flag.

Is there a "best" compounding pharmacy I should use? There is no single best pharmacy that is right for every patient. The right pharmacy for you is one that is properly licensed for your state, scores well on all seven evaluation criteria above, and operates within post-shortage compounding boundaries that match your clinical justification. Patient-specific recommendations require patient-specific evaluation.

What happens if I receive contaminated or under-dosed compounded semaglutide? Stop using the product immediately. Contact the pharmacy. Report to the FDA MedWatch program (1-800-FDA-1088 or online). If you experience an injection-site infection, fever, or other symptoms suggesting contamination, seek medical care promptly and bring the vial with you for laboratory testing.

Can a compounding pharmacy ship semaglutide across state lines? Yes, with proper licensing in both the dispensing state and the patient's state of residence. Many compounding pharmacies hold non-resident pharmacy licenses in multiple states. Confirm that the pharmacy is licensed to dispense to your state of residence.

Sources

1. FDA shortage list update on semaglutide, February 21, 2025.
2. FDA enforcement discretion guidance on compounded semaglutide, March-May 2025.
3. Drug Quality and Security Act of 2013, sections 503A and 503B.
4. USP <797> Pharmaceutical Compounding, Sterile Preparations, current revision.
5. FDA registered outsourcing facility list, current quarter.
6. Wilding et al., STEP-1 semaglutide weight loss trial, NEJM, 2021.
7. American Society of Health-System Pharmacists guidelines on outsourced sterile compounding, 2024.
8. FDA MedWatch adverse event reports related to compounded semaglutide, 2023-2025 dataset.
9. Lincoff et al., SELECT cardiovascular outcomes trial of semaglutide, NEJM, 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. All other brand names are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.